思派健康(00314) - 2025 - 年度业绩

Supplemental Announcement Overview This section provides an overview of the supplemental announcement, detailing its purpose and scope Purpose and Scope of Announcement This announcement supplements the 2024 annual report of Spai Health Technology Co., Ltd., providing additional information on the company's share schemes - This announcement supplements the 2024 annual report, primarily providing additional information on the company's share schemes (2017 Scheme, Restricted Share Unit Scheme, and 2023 Share Award Scheme)[3][9] - All other information in the annual report remains unchanged[9] Details of Share Scheme Updates This section provides updated details on the company's 2017 Scheme, Restricted Share Unit Scheme, and 2023 Share Award Scheme 2017 Scheme The 2017 Scheme's outstanding share options decreased between the annual report date and the announcement date, with a remaining term of approximately three years Outstanding Share Options Under 2017 Scheme | Grantee | Outstanding as of Annual Report Date (shares) | Approximate Percentage of Total Issued Shares (Annual Report Date) | Outstanding as of Announcement Date (shares) | Approximate Percentage of Total Issued Shares (Announcement Date) | | :--- | :--- | :--- | :--- | :--- | | Employees | 5,970,317 | 0.78% | 4,883,320 | 0.65% | | Service Providers | 804,900 | 0.11% | 733,900 | 0.10% | | Total | 6,775,217 | 0.89% | 5,617,220 | 0.75% | - As of the announcement date, the total outstanding share options under the 2017 Scheme decreased from 6,775,217 (0.89% of issued shares) on the annual report date to 5,617,220 (0.75% of issued shares)[4] - The 2017 Scheme commenced in January 2018 with a ten-year validity period, having approximately three years remaining as of the end of the reporting period[5] Restricted Share Unit Scheme The Restricted Share Unit Scheme had no outstanding units as of both dates and was resolved to be terminated early by the board due to all shares being vested Outstanding Restricted Share Units | Grantee | Outstanding as of Annual Report Date | Approximate Percentage of Total Issued Shares (Annual Report Date) | Outstanding as of Announcement Date | Approximate Percentage of Total Issued Shares (Announcement Date) | | :--- | :--- | :--- | :--- | :--- | | Zhou Teng | Nil | Nil | N/A | N/A | - As of both the annual report date and the announcement date, there were no outstanding restricted share units under Zhou Teng's name[6] - The Restricted Share Unit Scheme commenced in June 2021 with a ten-year validity period, having approximately six years remaining as of the end of the reporting period[7] - The Board resolved on August 18, 2025, to early terminate the Restricted Share Unit Scheme, as all relevant shares have been duly vested and the trustee holds no funds or property[7] 2023 Share Award Scheme The 2023 Share Award Scheme has a total cap of 8% of issued share capital, with 60,820,600 shares purchased by the trustee but none yet awarded - The total number of share awards under the 2023 Scheme is capped at 8% of the company's issued share capital as of the adoption date (approximately 7.99% as of the annual report date)[8] Share Purchases Under 2023 Scheme | Date | Total Shares Purchased (shares) | Approximate Percentage of Issued Share Capital (excluding treasury shares) | | :--- | :--- | :--- | | Annual Report Date | 42,297,400 | 5.56% | | Announcement Date | 60,820,600 | 8.10% | - As of the announcement date, the company has not yet awarded any shares under this scheme[8] - The 2023 Share Award Scheme commenced in August 2023 with a ten-year validity period, having approximately eight years remaining as of the end of the reporting period[9] Other Information This section provides additional information, including the composition of the Board of Directors Board of Directors Composition The announcement is signed by Mr. Ma Xuguang, Chairman and Executive Director, and details the board's composition as of the announcement date - The announcement is signed by Mr. Ma Xuguang, Chairman and Executive Director of the Board[10] - As of the announcement date, the Board members include Executive Directors Mr. Ma Xuguang and Mr. Li Ji; Non-executive Director Mr. Yao Leiwen; and Independent Non-executive Directors Mr. Fan Xin, Mr. He Haijian, and Ms. Huang Bei[11]